On February 5, 2018 Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) reported that it’s President, Chief Executive Officer and co-founder, Steven J. Mento, Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial Officer, Keith W. Marshall, Ph.D., M.B.A., will focus on the company’s expected announcements of clinical trial results and strategic development activities, in a presentation and in scheduled meetings with members of the investment community in New York next week (Press release, Conatus Pharmaceuticals, FEB 5, 2018, View Source [SID1234523755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is an exciting time for Conatus. We are now rapidly approaching four scheduled Phase 2b clinical trial readouts from our lead development program in 2018 and 2019, along with multiple parallel pathways to expanding our development pipeline," said Dr. Mento, "and we believe Conatus is advancing well toward the next chapter in the company’s evolution."

"With the funds provided by our collaboration with Novartis, including anticipated reimbursements for 50% of the costs for the four ongoing clinical trials," said Dr. Marshall, "the remaining emricasan development is fully funded. In addition, we believe these financial resources, without including any potential milestone payments under the Novartis collaboration, are sufficient to maintain operations through completion of all four Phase 2b clinical trials by the end of 2019, as well as to fund initial pipeline expansion activities. We will provide additional financial guidance for 2018 with our year-end financial results in early March."

At the Biotechnology Industry Organization (BIO) CEO & Investor Conference BIO CEO & Investor Conference in New York on Monday, February 12, Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 10:30 a.m. ET. An audio webcast and copy of the BIO CEO & Investor Conference presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.

At the SunTrust Robinson Humphrey Orphan Drug Day in New York on Tuesday, February 13, Dr. Mento and Dr. Marshall will conduct a series of meetings with invited institutional investors.

On February 5, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that Adelene Perkins, Infinity Pharmaceutical’s chief executive officer, will present at the BIO CEO & Investor Conference on Monday, February 12, 2018, at 11:00 a.m. EST at The New York Marriott in New York, NY (Press release, Infinity Pharmaceuticals, FEB 5, 2018, View Source [SID1234523725]). A live webcast of the presentation will be available on the Investors/Media section of Infinity’s website at www.infi.com, and will be available for 30 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 5, 2018 Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") reported that it will be attending and presenting at the BIO CEO & Investor Conference being held on February 12 – 13, 2018 at the New York Marriott Marquis (Press release, Actinium Pharmaceuticals, FEB 5, 2018, View Source [SID1234523729]). Details of Actinium’s presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, February 13, 2018
Time: 9:15 AM ET
Room: Odets, 4th Floor
Venue: New York Marriott Marquis, 1535 Broadway, New York, NY 10036

Management will be conducting 1-on-1 meetings during the conference. To arrange a meeting with Actinium please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at [email protected] or utilize the conference’s partnering system View Source

On February 5, 2018 Varian (NYSE: VAR) reported it has acquired privately-held Mobius Medical Systems, a leader in radiation oncology Quality Assurance (QA) software (Press release, Varian Medical Systems, FEB 5, 2018, View Source [SID1234523897]). This acquisition expands Varian’s leadership in radiation medicine, by increasing its portfolio of patient treatment plan QA and machine QA technologies, and enables the company to potentially impact more patients around the globe with software solutions designed to assure the quality of treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The acquisition of Mobius is consistent with Varian’s long-term growth and value creation strategy and broadens its cancer care portfolio. The integration of additional QA tools into the Varian ecosystem will allow advanced QA processes to be more seamlessly combined into treatment workflows. Additionally, Varian also can ensure that QA methods advance at the same time as Varian introduces new treatment techniques.

"Varian has a long history of providing high-quality QA for its products and the treatments they deliver," said Kolleen Kennedy, president of Varian’s Oncology Systems business. "Varian places high value on the market-leading Mobius QA products, including Mobius3D and DoseLab, and is dedicated to expanding their global reach. The two companies have similar cultures with deep commitments to enabling quality cancer care for patients around the globe."

The Mobius QA software is in use at over 1000 sites worldwide to ensure patients receive high-quality care. Mobius3D is a 3D dose verification and IMRT/VMAT treatment delivery QA system. Mobius3D performs 3D dose verification for patient plans, supports verification checks throughout the entire clinical process for IMRT and VMAT, and includes modular staged testing to reinforce the confidence of the medical physicist in the patient plan and treatment delivery. DoseLab is fast, simple and powerful software for quality assurance of medical linear accelerators.

For more information about the Mobius products that are now part of the Varian cancer care portfolio, visit www.varian.com/mobius.

On February 5, 2018 Yuhan Corporation (KRX:000100.KS) (Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq:SRNE) (Sorrento) reported that the South Korean Ministry of Food and Drug Safety (MFDS) has approved ImmuneOncia Therapeutics’ (51% Yuhan/49% Sorrento joint venture formed in March 2016) IND for the initiation of clinical trials for Sorrento-discovered anti-PD-L1 monoclonal antibody STI-A1015 (IMC-001), which is exclusively licensed to ImmuneOncia for select regional markets by Sorrento (Press release, ImmuneOncia Therapeutics, FEB 5, 2018, View Source [SID1234531898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Yuhan had initially contributed more than $10M to the formation of ImmuneOncia and towards the development of IMC-001, with a commitment of additional funding for clinical development of IMC-001. Sorrento contributed its antibody STI-A1015 (IMC-001) and two other antibodies, as well as cGMP manufacturing and regulatory expertise support for the data submission package for the IND.

The clinical Phase 1 studies will enroll patients suffering from solid tumors at two clinical sites in South Korea, namely, Seoul National University Hospital (SNUH) and Samsung Medical Center (SMC).

"We are proud to announce the acceptance of the IND by MFDS for our anti-PD-L1 antibody IMC-001. Throughout the IND-enabling activities, our team has worked collaboratively with our Sorrento colleagues to generate a high-quality submission package that was very well received by MFDS", said Dr. Kwang Ho Cheong, CEO of ImmuneOncia Therapeutics.

"Yuhan is proud of this outstanding achievement by Dr. Cheong and the ImmuneOncia team. Together with our friends and partners from Sorrento, we created ImmuneOncia to develop important immunotherapies for cancer patients in South Korea and worldwide. Through our investment in ImmuneOncia, Yuhan has become a true biopharmaceutical company. We look forward to the future success of IMC-001 and the other antibody programs in ImmuneOncia’s pipeline", said Mr. Jung Hee Lee, CEO and President of Yuhan Corporation.

"We are very pleased with the progress made by our joint venture in the past year. We believe this is additional validation of our antibody technology as well as our in-house cGMP antibody manufacturing and development capabilities. Notably, Sorrento has retained the rights for STI-A1015 (IMC-001) in many major markets, including the EU, Japan and the US, and we intend to leverage ImmuneOncia’s clinical work to support our clinical development in these territories where we retain rights to STI-A1015 (IMC-001). We also think the success of ImmuneOncia further highlights our ability to create shareholder value through productive strategic partnerships," added Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.

ImmuneOncia is exploring being publicly-listed on the South Korea Stock Exchange (KSEX) in 2019, which could result in additional sources of non-dilutive capital for Sorrento.

About IMC-001 (PD-L1 monoclonal antibody)

IMC-001 is a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, then suppressing the inhibition of PD-1/PDL1 signal to T cells and enhancing the killing effect of T cells on tumors. This antibody also kills cancer cells through traditional antibody-dependent cell-mediated cytotoxicity (ADCC) recruiting Natural Killer (NK) cells and other effector cells against the tumor potentially further strengthening the anti-tumor effect of the antibody